SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Anil Chakravarthy was appointed President and Chief Executive Officer of Adobe effective December 1, 2026, and elected to the Board of Directors. Shantanu Narayen transitioned to Executive Chair, and David Wadhwani departed. The Board unanimously determined Chakravarthy is the right leader for Adobe's next chapter of growth.
View raw filing on EDGAR →Robert Kuhns was appointed as Executive Vice President and Chief Financial Officer of MSC Industrial Direct Co Inc, effective September 14, 2026, bringing 30+ years of financial expertise and prior CFO experience at TopBuild Corp. The appointment includes a $650,000 base salary, $1.5M sign-on equity grant, and change-of-control severance provisions. Greg Clark's resignation as Interim CFO is also disclosed in connection with this permanent appointment.
View raw filing on EDGAR →Thomas S. Gayner appointed to the additional role of Chairman effective September 8, 2026, succeeding Steven A. Markel. Simon Wilson appointed as Co-President and CEO of Markel Insurance, and Andrew G. Crowley appointed as Co-President and CEO of Markel Ventures, representing a significant leadership transition at the top of the organization.
View raw filing on EDGAR →The filing centers on the appointment of Ms. Sumita Pandit as Senior Vice President and Chief Financial Officer effective September 9, 2026, with detailed disclosure of her background, employment agreement terms (including $750,000 base salary, $3,000,000 one-time bonus, and equity awards totaling $5,350,000 in PSUs and RSUs), and severance provisions. While Mr. Weiner's departure as CFO is also disclosed, the principal action and the bulk of the disclosure focuses on Pandit's appointment to this material executive role. The appointment of a new CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →The filing announces the appointment of Metin Tuğtağ as Chief Sales Officer effective September 9, 2026, following the resignation of Kadri Özdal. While both a departure and appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite role (Chief Sales Officer). The appointment of a CSO is material to investors as it affects the company's sales leadership and strategy.
View raw filing on EDGAR →Michele Harradence was appointed as President and Chief Executive Officer effective January 1, 2027, and concurrently appointed to the Board of Directors, succeeding retiring CEO Greg Ebel following a multi-year succession planning process. This represents a material executive leadership transition at the major energy infrastructure company.
View raw filing on EDGAR →AdaptHealth appointed Harriss Currie as Chief Financial Officer effective September 9, 2026, with a base salary of $670,000, 100% target bonus, and $818,462 in RSUs. The appointment replaces Jason Clemens' departure as CFO and represents a material change in the company's financial leadership.
View raw filing on EDGAR →Serge Zappone was appointed as President, International and Senior Vice President of Allegion, effective January 1, 2027, succeeding Timothy P. Eckersley and reporting to the CEO.
View raw filing on EDGAR →Steven Ryder was appointed as Chief Financial Officer of Clearway Energy, Inc., effective October 1, 2026, succeeding Sarah Rubenstein. Samantha Prout was also appointed as SVP Accounting and Controller (principal accounting officer). Sarah Rubenstein transitioned to Head of Transformation Office at the parent company.
View raw filing on EDGAR →Steven Ryder was appointed as Chief Financial Officer of Clearway Energy LLC effective October 1, 2026, succeeding Sarah Rubenstein. Simultaneously, Samantha Prout was appointed as Senior Vice President, Accounting and Controller, effective immediately, also succeeding Rubenstein in her principal accounting officer role. These appointments represent material changes to the company's financial leadership.
View raw filing on EDGAR →The filing discloses the appointment of Brent Moen as Chief Financial Officer effective September 11, 2026, with detailed compensation arrangements including a $475,000 base salary, bonus opportunity, and $500,000 long-term incentive award. While the section also mentions Matthew McDonnell's transition from CFO to Head of Australia, the principal disclosed action centers on the appointment of a new CFO, a material executive position. This is a clear exec_appointment event.
View raw filing on EDGAR →Shutterstock appointed three new directors—Timothy Adams, Matthew Salzberg, and Michael Thompson—to its Board of Directors, effective September 8, 2026, as Class II and Class III directors based on the Nominating Committee's recommendation. The appointees bring extensive financial, operational, investment, and technology expertise to strengthen the Board's governance.
View raw filing on EDGAR →Northern Technologies International Corp announced a planned executive succession effective September 4, 2026, with Gautam Ramdas appointed as President and Chief Executive Officer and elected to the Board, Brian Haglund appointed as Chief Operating Officer, G. Patrick Lynch transitioning from CEO to Chairman, and Richard Nigon appointed as lead independent director. The appointments include compensation arrangements for the new executives.
View raw filing on EDGAR →The exhibit announces the appointment of Martin Dewhurst to NovaBridge's Board of Directors as an independent director and member of the Audit and Compensation Committees, effective immediately. This is a clear governance event involving the appointment of a named executive/director with substantial healthcare and board experience. The disclosure also notes the concurrent departure of independent director Liu Xin, but the principal action disclosed is Dewhurst's appointment to the board and committees.
View raw filing on EDGAR →The filing discloses the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026. While the disclosure includes compensatory details (base salary of $550,000, bonus eligibility, equity awards of 450,000 options and 173,438 PSUs, and severance provisions), the principal action is the appointment of a named executive officer to a key financial leadership role. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →Aatish V Patel ceased serving as President of XCHG Limited and was appointed General Manager of the Company's wholly-owned U.S. subsidiary, XCharge Energy USA Inc., effective September 7, 2026. While this involves both a departure from one role and an appointment to another, the filing emphasizes the appointment to the subsidiary leadership position as the principal action, framed as a strategic reassignment to strengthen U.S. operations. The amendment to his offer letter and the material nature of a President-level executive's repositioning make this material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →Thomas Civik was appointed as permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, transitioning from his interim role since February 2026. The appointment includes compensatory arrangements (stock option grant and sign-on bonus), severance terms, and related governance changes including John Flavin's transition to Lead Independent Director and Dr. Palani's resignation.
View raw filing on EDGAR →Glenn Boehnlein was appointed to the Board of Directors effective September 4, 2026, bringing significant financial and medical-technology sector expertise. Concurrently, Board Chair Boon Hwee Koh retired on the same date, and Dow R. Wilson was elected as the new Board chair.
View raw filing on EDGAR →The Board appointed Benjamin Graboske as a Class III director effective immediately, with a term expiring at the 2027 Annual Meeting. This is a clear director appointment disclosed under Item 5.02. While the section also mentions director compensation arrangements, the principal disclosed action is the appointment itself, not a compensation modification. The appointment is material as it expands the Board from six to seven members and affects governance structure.
View raw filing on EDGAR →Xponential Fitness appointed Jennifer Ryu as Chief Financial Officer, effective October 19, 2026, succeeding interim CFO Robert Julian. The appointment includes a base salary of $550,000, target bonus of 60%, sign-on bonus of $150,000, and equity grants valued at $1.7 million.
View raw filing on EDGAR →Three executives were promoted effective October 1, 2026: Gary Campbell to President, Americas; Brian Hatcher to President, Recon, S.E.T., CMFT, Neuro and Biosurgery; and Bradley Kessler to President, Americas – Robotics, Technology and Data. All three will report directly to the CEO as part of a leadership restructuring designed to streamline operations.
View raw filing on EDGAR →The filing discloses the appointment of Christopher Jensen as Chief Executive Officer and Board member effective September 8, 2026, along with concurrent compensatory arrangements (base salary $450,000, performance bonus, and RSU eligibility). While Edward Chen's resignation as CEO is also mentioned, the principal disclosed action centers on Jensen's appointment to lead day-to-day operations of a Nasdaq-listed company. The filing also discloses a concurrent employment agreement with CFO Young Cho, but Jensen's CEO appointment is the primary event. This is material to investors as it represents a significant leadership change at a recently public company (IPO in June 2026).
View raw filing on EDGAR →Michael P. Pell was elected as an Ohio member director of the Federal Home Loan Bank of Cincinnati's board of directors for a four-year term commencing January 1, 2027, confirming board leadership continuity.
View raw filing on EDGAR →Kiora Pharmaceuticals appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026. Lane brings 20+ years of ophthalmology experience and previously served as Chief Scientific Officer at Ora, Inc. The appointment includes compensatory terms of $350,000 base salary, $75,000 sign-on bonus, 35% performance bonus target, and 55,000 stock options.
View raw filing on EDGAR →Loop Industries announced the appointment of Jeffrey R. Geygan as Chairman of the Board of Directors, with founder and CEO Daniel Solomita retaining his CEO role but relinquishing the Chairman title. This represents a material governance change involving the appointment of a new board leader with significant capital-markets and public-company experience, coupled with a structural separation of the Chairman and CEO roles. The press release emphasizes this as strengthening corporate governance and enabling focused commercial execution.
View raw filing on EDGAR →David Garcia Rios was appointed as a Class II director of the Board, effective September 2, 2026, exercising SFF's contractual board designation right under the January 2026 Investors' Rights Agreement. Garcia Rios brings expertise in digital assets and corporate governance to the cryptocurrency-focused company.
View raw filing on EDGAR →The filing discloses the promotion of Thomas Englese to Chief Commercial Officer of Tonix Pharmaceuticals, effective immediately on September 8, 2026. Englese had previously served as Executive Vice President of Commercial Operations since September 2024 and will now lead the company's commercial organization overseeing sales, marketing, and market access for TONMYA and other marketed products. This is a material executive appointment to a C-suite officer role at a commercial-stage biopharmaceutical company.
View raw filing on EDGAR →Timothy A. Peterman was appointed as Acting CFO of Laser Photonics Corporation on September 8, 2026, replacing Ralph Venegas who resumed his prior position as VP of Finance and Reporting. This is a material executive appointment disclosed under Item 5.02, as the CFO is a named executive officer whose appointment affects investor assessment of the company's financial leadership and governance.
View raw filing on EDGAR →The filing discloses the appointment of Martín de los Ríos Plaza as a Regular Director for Class D shares by the Supervisory Committee, replacing the resigned director Maximiliano D'Alessio. While the resignation is also mentioned, the principal disclosed action is the appointment of a new director to fill the vacancy. Board-level director appointments are material governance events affecting the composition of the registrant's leadership.
View raw filing on EDGAR →Simeon Kohl was appointed as Chief Executive Officer, President, principal executive officer, principal operating officer, and Board member of Health Catalyst, Inc., effective September 14, 2026. Ben Albert transitioned from CEO to Chief Business Officer in connection with this succession. Kohl brings over 20 years of healthcare leadership experience, including his track record at Performant Healthcare.
View raw filing on EDGAR →John M. Sullivan has been appointed to VICI Properties' Board of Directors as an independent director, effective upon regulatory approvals. The disclosure centers on the principal action of a person taking a board role, with details on his committee assignments and qualifications. This is a clear exec_appointment event. The appointment is material as it affects board composition and governance at a large S&P 500 REIT.
View raw filing on EDGAR →The filing discloses the appointment of Rob Myers, M.D., as Chief Medical Officer effective September 21, 2026, to succeed Joanne Quan, M.D. While the section also describes Dr. Quan's departure and associated severance arrangements, the principal announced action is the appointment of a new CMO to a named executive officer role. The appointment of a C-suite executive is material to investors assessing company leadership and continuity.
View raw filing on EDGAR →Jeffrey Bertolini was appointed Chief Operating Officer of Carlsmed, Inc., effective September 8, 2026, by the Board of Directors on September 4, 2026. The appointment includes compensatory arrangements with a salary increase to $475,000, target incentive opportunity increased to 60%, and a grant of 50,000 stock options. Bertolini was promoted from Senior Vice President of Operational Excellence and brings senior leadership experience from major medical device companies including SI-BONE, NuVasive, and US Surgical.
View raw filing on EDGAR →The filing discloses the appointment of Gildas Bonnier as Interim Chief Financial Officer effective September 4, 2026. Although the role is interim and a permanent CFO search is underway, the appointment of a principal financial officer is a material executive appointment that would affect investor assessment of the company's financial leadership and governance. The detailed biographical information and compensation terms ($10,000/month consulting fee) confirm this is a substantive appointment disclosure.
View raw filing on EDGAR →The Board approved the appointment of Frank Dixon Whitworth III as President of Satellogic Inc., effective September 7, 2026. While the disclosure includes compensatory details (base salary of $400,000, performance bonus target of $240,000, and RSU grants), the principal disclosed action is the appointment of a named executive officer to a senior leadership position. The compensation terms are ancillary to the appointment itself, making exec_appointment the most salient classification.
View raw filing on EDGAR →The Board of Directors elected Michael J. Katz as a Class II director effective September 3, 2026, to serve until the 2027 annual meeting. This is a clear director appointment with detailed disclosure of his qualifications, including his extensive leadership experience at T-Mobile and recognition as one of Forbes' 50 most influential CMOs. Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →Concentra Group Holdings Parent, Inc. announced a leadership succession involving the appointment of Tanner Newton as Executive Vice President and Chief Financial Officer effective November 1, 2026, concurrent with the promotion of Matthew DiCanio to President and CEO and Keith Newton to Executive Chairman.
View raw filing on EDGAR →Jack Weingart was appointed Chairperson of the T-POP Board effective September 6, 2026, in addition to his existing roles as CEO and board member. While Todd Sisitsky's concurrent resignation as Chairperson is disclosed, the principal action disclosed is Weingart's appointment to the chair role, making this an exec_appointment event. The appointment of a CEO to chair is material to investors' understanding of governance and leadership structure.
View raw filing on EDGAR →Laird Superfood appointed Mark Johnson as Chief Financial Officer effective October 1, 2026. Johnson brings 25+ years of finance leadership experience in CPG companies and will serve as the company's principal financial officer and principal accounting officer reporting to the CEO, with a base salary of $375,000, bonus eligibility, and severance terms.
View raw filing on EDGAR →Keith Stauffer was appointed as Vice President, Global Finance effective September 7, 2026, and Chief Financial Officer effective November 2, 2026. The appointment includes comprehensive compensation arrangements including base salary, equity awards, and a sign-on bonus.
View raw filing on EDGAR →AC Immune SA held an Extraordinary General Meeting to propose the election of Tom Graney to the Board of Directors and the Audit and Finance Committee. Graney, who previously served on the board from 2016–2023, brings significant biotech and CFO/CEO experience to the company.
View raw filing on EDGAR →Halide Alagoz was appointed Chief Operating & Product Officer, effective November 29, 2026, with expanded responsibilities including AI strategy and architecture & design, following Bob Ranftl's retirement as Chief Operating Officer. This represents a significant change in the Company's operational leadership structure.
View raw filing on EDGAR →The filing discloses the appointment of three new directors (Richard Shorten, Todd Larsen, and Lok Lee) effective September 3, 2026, to fill vacancies created by three resignations. While both departures and appointments occur, the principal disclosed action centers on the Board's appointment of the new directors and their committee assignments. The appointment of Richard Shorten is particularly material given his significant related-party transactions: he controls Silvermine Capital Advisors (40% owner of GlobalStake), which serves as investment adviser to Comstock MultiChain Fund—a current shareholder that participated in prior PIPEs and has ongoing financial relationships with the Company totaling millions in proceeds and warrant exercises.
View raw filing on EDGAR →Ragnar Udd has been appointed President and Chief Executive Officer of Albemarle effective February 1, 2027, and will join the Board of Directors. The appointment follows a comprehensive Board succession planning process and includes detailed compensatory arrangements (base salary $1.3M, sign-on bonus $1.4M, make-whole equity awards of $11M, and 2027 LTI awards of $7.5M). J. Kent Masters transitions from CEO to Executive Chairman as part of a well-defined succession plan.
View raw filing on EDGAR →Richard R. Fabian was appointed President of Profound Medical effective September 1, 2026, succeeding Mathieu Burtnyk who transitioned to Chief Technology Officer. Fabian brings 29+ years of healthcare industry experience, including prior roles as CEO of FUJIFILM Sonosite and executive positions at Philips Healthcare and STERIS, with a compensation package of $550,000 base salary, up to 100% bonus, 200,000 RSUs, and 475,000 options.
View raw filing on EDGAR →Joseph M. Miller has been appointed as Chief Financial Officer of LB Pharmaceuticals effective September 2, 2026. The appointment includes compensatory arrangements comprising a base salary of $530,000, a target bonus of 40%, and an equity option grant of 200,000 shares. Miller brings extensive biopharmaceutical finance experience and will support the company through a potentially transformative period including pivotal clinical trial results and potential commercialization of LB-102.
View raw filing on EDGAR →CarGurus announced the appointment of Matthew Mandel as Chief Financial Officer, effective October 19, 2026, with a compensation package including a $450,000 base salary, $450,000 target bonus, $250,000 sign-on bonus, and $5.5 million in RSUs. Mandel succeeds Jason Trevisan, who served as interim CFO since March 2025.
View raw filing on EDGAR →T-Mobile appointed Jessica Uhl as Chief Financial Officer Designate effective mid-September 2026, with transition to CFO in February 2027, succeeding Peter Osvaldik. The appointment includes detailed compensation terms: $975,000 base salary, $1M sign-on bonus, and $9.525M in long-term incentive awards.
View raw filing on EDGAR →David Buss was appointed as Senior Vice President and Chief Operating Officer effective August 31, 2026. Mr. Buss brings over 30 years of transportation and logistics leadership experience, including prior CEO roles at DB Schenker, and will receive a base salary of $250,000 with severance provisions and incentive compensation eligibility.
View raw filing on EDGAR →The filing announces the appointment of Dr. Jialin Lu as an independent director and member of three board committees, with designation as chairperson of the nominating and corporate governance committee, effective September 3, 2026. While the filing also discloses the resignation of Ms. Sha Ye, the principal disclosed action is the appointment of a new director to a material governance role. Board composition changes affecting independent director representation and committee leadership are material to investors assessing governance quality.
View raw filing on EDGAR →